-
New Approach to Measuring C-Peptide Could Improve Type 1 Diabetes Trials
A proposed longitudinal C-peptide endpoint may offer researchers a more sensitive and informative way to evaluate treatments aimed at preserving insulin production in type 1 diabetes trials.
-
TwoStep Therapeutics Secures $62.5 Million Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate
TwoStep Therapeutics has closed an oversubscribed $62.5 million Series A financing round and received FDA clearance to begin clinical trials of its first-in-class peptide-drug conjugate therapy.
-
New Phase I Trial Launches for Novel WRN-Targeting Peptide-Based Therapy in Advanced Cancers
A first-in-human trial is now testing VVD-133214, an oral compound designed to target the Werner (WRN) protein, offering new hope for patients with MSI and dMMR advanced solid tumors.
-
New Clinical Trial Explores Enhanced Combination Therapy for Lymphoma Patients
A new study is investigating whether adding zilovertamab vedotin to standard chemotherapy could help newly diagnosed DLBCL patients live longer without cancer progression. The trial compares this combination against the current standard treatment regimen.
-
New Clinical Trial Explores Xeomin’s Potential to Prevent Episodic Migraine
A new clinical trial is underway to evaluate whether Xeomin injections can help reduce monthly migraine days in people with episodic migraine, compared to placebo.
-
New Phase 3 Trial Launches to Explore Novel Antibody-Drug Conjugate for Advanced Colorectal Cancer
A large global Phase 3 trial is now underway comparing an investigational antibody-drug conjugate, telisotuzumab adizutecan, plus bevacizumab against standard therapy for refractory metastatic colorectal cancer, offering new hope for patients with limited treatment options.
-
New Clinical Trial Explores Tirzepatide for Childhood Obesity in Kids Ages 6–11
A new study is evaluating whether tirzepatide, combined with healthy lifestyle support, can safely and effectively help children ages 6 to 11 manage obesity, with an extension phase offering continued treatment access.
-
New Clinical Trial Explores Odronextamab as a Potential Advance for Lymphoma Patients
A new clinical trial is evaluating whether odronextamab, an investigational antibody therapy, combined with chemotherapy could offer a promising new option for patients newly diagnosed with diffuse large B-cell lymphoma. The study compares this approach to the current standard of care.
-
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for Cholesterol Management
Merck’s Lipfendra has received FDA approval as the world’s first oral PCSK9-targeting treatment, offering a needle-free option for patients managing high cholesterol.
-
FDA Panel Vote Could Expand Access to Popular Peptides for Millions
A recent FDA advisory panel vote signals a potential pathway toward easier, broader access to some of the most sought-after peptide compounds, a move that could benefit millions of patients and consumers.